Himu Lukka

7.4k total citations · 1 hit paper
77 papers, 4.4k citations indexed

About

Himu Lukka is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Oncology. According to data from OpenAlex, Himu Lukka has authored 77 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 21 papers in Radiation and 18 papers in Oncology. Recurrent topics in Himu Lukka's work include Prostate Cancer Treatment and Research (45 papers), Prostate Cancer Diagnosis and Treatment (36 papers) and Advanced Radiotherapy Techniques (21 papers). Himu Lukka is often cited by papers focused on Prostate Cancer Treatment and Research (45 papers), Prostate Cancer Diagnosis and Treatment (36 papers) and Advanced Radiotherapy Techniques (21 papers). Himu Lukka collaborates with scholars based in Canada, United States and Australia. Himu Lukka's co-authors include Mark N. Levine, Jim A. Julian, Timothy J. Whelan, Ian S. Dayes, Sameer Parpia, Anthony Fyles, Jean‐Philippe Pignol, Carolyn Freeman, Sunil Gulavita and L. Grimard and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

Himu Lukka

73 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

2010 1.3k citations Timothy J. Whelan, Jim A. Julian et al. profile →

Peers

Countries citing papers authored by Himu Lukka

Since Specialization

Citations

This map shows the geographic impact of Himu Lukka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Himu Lukka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Himu Lukka more than expected).

Fields of papers citing papers by Himu Lukka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Himu Lukka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Himu Lukka. The network helps show where Himu Lukka may publish in the future.

Co-authorship network of co-authors of Himu Lukka

This figure shows the co-authorship network connecting the top 25 collaborators of Himu Lukka. A scholar is included among the top collaborators of Himu Lukka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Himu Lukka. Himu Lukka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer 2025 ·European Urology Oncology ·(unknown), Ian S. Dayes, Charles Catton, Amy Liu, S. Supiot, Himu Lukka, Glenn Bauman, (unknown), Jean-Paul Bahary, Shahida Ahmed, Patrick Cheung, Matthew Parliament, Michael Sia, Theodoros Tsakiridis, Shankar Siva, Tom Corbett, Colin Tang, Tim Craig, Jarad Martin, Peter Chung	1
2	Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy 2025 ·International Journal of Radiation OncologyBiologyPhysics ·Himu Lukka, Stephanie L. Pugh, William U. Shipley, Pierre Major, Oliver Sartor, Ian S. Dayes, Jean-Paul Bahary, Jason A. Efstathiou, Thomas M. Pisansky, Kenneth L. Zeitzer, C.A. Lawton, Robert T. Dess, (unknown), Alexander G. Balogh, Luís Souhami, Seth A. Rosenthal, (unknown), Wendy Seiferheld, Felix Y. Feng, Howard M. Sandler	1
3	The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments 2021 ·Clinical Genitourinary Cancer ·Aruz Mesci, (unknown), Ian S. Dayes, Himu Lukka, Theodoros Tsakiridis	6
4	Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Julie Arsenault, Sameer Parpia, (unknown), Eileen Rakovitch, Harold Reiter, Mary Doherty, Himu Lukka, Jonathan Sussman, James R. Wright, Jim A. Julian, Timothy J. Whelan	46
5	Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases 2019 ·Asian Journal of Andrology ·Anil Kapoor, (unknown), Yuding Wang, Som D. Mukherjee, Sébastien J. Hotte, Ian S. Dayes, Himu Lukka	1
6	Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data 2016 ·Clinical Oncology ·Andrew Loblaw, Tom Pickles, Juanita Crook, André‐Guy Martin, Éric Vigneault, Luís Souhami, Fabio Cury, James Morris, Charles Catton, Himu Lukka, Patrick Cheung, Perakaa Sethukavalan, A. Warner, Ying Yang, George Rodrigues	20
7	Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01 2016 ·Urologic Oncology Seminars and Original Investigations ·Raymond H. Mak, Daniel Hunt, Jason A. Efstathiou, Niall M. Heney, Christopher U. Jones, Himu Lukka, Jean-Paul Bahary, Malti Patel, (unknown), Abdenour Nabid, Mark H. Leibenhaut, Daniel A. Hamstra, Kevin S. Roof, (unknown), Elizabeth Gore, Howard M. Sandler, William U. Shipley	14
8	Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer 2015 ·Cureus ·Andrew Warner, Tom Pickles, Juanita Crook, André‐Guy Martin, Luís Souhami, Charles Catton, Himu Lukka, George Rodrigues	9
9	Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation 2015 ·Oncology Reports ·Wilhelmina Duivenvoorden, Sarah Hopmans, Daniel Gallino, Thomas J. Farrell, (unknown), (unknown), Himu Lukka, Jehonathan H. Pinthus	17
10	The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis 2014 ·Journal of the National Comprehensive Cancer Network ·George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luís Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, André‐Guy Martin, Éric Vigneault, (unknown), Andrew Warner, Sandra González Maldonado, Tom Pickles, (unknown)	10
11	The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis 2013 ·Radiotherapy and Oncology ·George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luís Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, André‐Guy Martin, Éric Vigneault, (unknown), Andrew Warner, Sandra González Maldonado, Tom Pickles	27
12	Pre-treatment risk stratification of prostate cancer patients: A critical review 2012 ·Canadian Urological Association Journal ·George Rodrigues, Padraig Warde, Tom Pickles, Juanita Crook, Michael Brundage, Luís Souhami, Himu Lukka	101
13	Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways 2011 ·Radiation Oncology ·Ayesha Rashid, Caiqiong Liu, Toran Sanli, Evangelia Tsiani, Gurmit Singh, Robert G. Bristow, Ian S. Dayes, Himu Lukka, James R. Wright, Theodoros Tsakiridis	86
14	Management of Stage I Seminomatous Testicular Cancer: a Systematic Review 2009 ·Clinical Oncology ·Peter Chung, (unknown), Padraig Warde, Eric Winquist, Himu Lukka	42
15	Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis 2008 ·Radiotherapy and Oncology ·Scott C. Morgan, T. Waldron, Libni Eapen, (unknown), Eric Winquist, Himu Lukka	57
16	Adjuvant radiotherapy in women with stage I endometrial cancer: A systematic review 2006 ·Gynecologic Oncology ·Himu Lukka, Alexandra Chambers, Anthony Fyles, Kullathorn Thephamongkhol, Michael Fung‐Kee‐Fung, Laurie Elit, Janice S. Kwon	18
17	Follow-up after primary therapy for endometrial cancer: A systematic review 2006 ·Gynecologic Oncology ·Michael Fung‐Kee‐Fung, Jason Dodge, Laurie Elit, Himu Lukka, (unknown), Tom Oliver	240
18	Combined gamma‐irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin 2004 ·International Journal of Radiation Biology ·(unknown), Gurmit Singh, Himu Lukka, Andrew J. Rainbow	9
19	Accuracy of ultrasound in localization of breast boost field 2004 ·Radiotherapy and Oncology ·Jolie Ringash, Timothy J. Whelan, (unknown), Terry Minuk, (unknown), Himu Lukka, Harold Reiter	34
20	Phase II Study to Evaluate the Toxicity and Efficacy of Concurrent Cisplatin and Radiation Therapy in the Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Cervix 1995 ·Gynecologic Oncology ·R. Pearcey, Gavin Stuart, Grant D. MacLean, Jill Nation, Keith Arthur, Himu Lukka, John Jeffrey, Keith James, Michael Brundage	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact